Immunotherapy in prion disease

Nature Reviews Neurology

Volumn 9, Issue 2, 2013, Pages 98-105

  Roettger, Yvonne ^a   Du, Yansheng ^b   Bacher, Michael ^a   Zerr, Inga ^c   Dodel, Richard ^a   Bach, Jan Philipp ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ENZYME; CHOLERA TOXIN; FREUND ADJUVANT; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 6H4; MONOCLONAL ANTIBODY N3; MONOCLONAL ANTIBODY S18; POLYCLONAL ANTIBODY; POLYCLONAL ANTIBODY W3; PRION PROTEIN; PRION PROTEIN ANTIBODY; SUCCINYLARGININE DIHYDROLASE; UNCLASSIFIED DRUG; VIRUS VECTOR;

ACTIVE IMMUNIZATION; ADJUVANT THERAPY; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; CREUTZFELDT JAKOB DISEASE; FOLLICULAR DENDRITIC CELL; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; MUCOSAL IMMUNITY; NONHUMAN; PASSIVE IMMUNIZATION; PRION DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEIN MISFOLDING; PROTEIN TRANSPORT; REVIEW; SCRAPIE;

ANIMALS; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOTHERAPY; PRION DISEASES; PRIONS; VACCINATION;

EID: 84873728561     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2012.258     Document Type: Review

References (103)

1. Prusiner, S. B. The prion diseases. Brain Pathol. 8, 499-513 (1998). (Pubitemid 28308848)
2. McKinley, M. P., Bolton, D. C. & Prusiner, S. B. A protease-resistant protein is a structural component of the scrapie prion. Cell 35, 57-62 (1983). (Pubitemid 14240218)
3. Collinge, J. Prion diseases of humans and animals: their causes and molecular basis. Annu. Rev. Neurosci. 24, 519-550 (2001). (Pubitemid 32695238)
4. Fraser, H. & Dickinson, A. G. Pathogenesis of scrapie in the mouse: the role of the spleen. Nature 226, 462-463 (1970).
5. Brown, P. Creutzfeldt-Jakob disease: reflections on the risk from blood product therapy. Haemophilia 13 (Suppl. 5), 33-40 (2007). (Pubitemid 350253402)
6. Hilton, D. A. et al. Specificity of lymphoreticular accumulation of prion protein for variant Creutzfeldt-Jakob disease. J. Clin. Pathol. 57, 300-302 (2004). (Pubitemid 38338845)
7. Glatzel, M., Abela, E., Maissen, M. & Aguzzi, A. Extraneural pathologic prion protein in sporadic Creutzfeldt-Jakob disease. N. Engl. J. Med. 349, 1812-1820 (2003). (Pubitemid 37362957)
8. Zerr, I. Therapeutic trials in human transmissible spongiform encephalopathies: recent advances and problems to address. Infect. Disord. Drug Targets 9, 92-99 (2009).
9. Dormont, D. Approaches to prophylaxis and therapy. Br. Med. Bull. 66, 281-292 (2003). (Pubitemid 37173508)
10. Brody, D. L. & Holtzman, D. M. Active and passive immunotherapy for neurodegenerative disorders. Annu. Rev. Neurosci. 31, 175-193 (2008).
11. Oesch, B. et al. A cellular gene encodes scrapie PrP 27-30 protein. Cell 40, 735-746 (1985). (Pubitemid 15240279)
12. Kretzschmar, H. A., Prusiner, S. B., Stowring, L. E. & DeArmond, S. J. Scrapie prion proteins are synthesized in neurons. Am. J. Pathol. 122, 1-5 (1986). (Pubitemid 16108541)
13. Harris, D. A. Cellular biology of prion diseases. Clin. Microbiol. Rev. 12, 429-444 (1999). (Pubitemid 29330138)
14. Bueler, H. et al. Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature 356, 577-582 (1992).
15. Tobler, I. et al. Altered circadian activity rhythms and sleep in mice devoid of prion protein. Nature 380, 639-642 (1996). (Pubitemid 26119019)
16. Colling, S. B., Khana, M., Collinge, J. & Jefferys, J. G. Mossy fibre reorganization in the hippocampus of prion protein null mice. Brain Res. 755, 28-35 (1997). (Pubitemid 27191996)
17. Forloni, G. et al. A neurotoxic prion protein fragment induces rat astroglial proliferation and hypertrophy. Eur. J. Neurosci. 6, 1415-1422 (1994).
18. Whatley, S. A. et al. Regulation of intracellular free calcium levels by the cellular prion protein. Neuroreport 6, 2333-2337 (1995). (Pubitemid 26013122)
19. Brown, D. R., Schulz-Schaeffer, W. J., Schmidt, B. & Kretzschmar, H. A. Prion protein-deficient cells show altered response to oxidative stress due to decreased SOD 1 activity. Exp. Neurol. 146, 104-112 (1997). (Pubitemid 27319724)
20. Brown, D. R. & Mohn, C. M. Astrocytic glutamate uptake and prion protein expression. Glia 25, 282-292 (1999). (Pubitemid 29060224)
21. Mouillet-Richard, S. et al. Signal transduction through prion protein. Science 289, 1925-1928 (2000).
22. Weise, J. et al. Upregulation of cellular prion protein (PrPc) after focal cerebral ischemia and influence of lesion severity. Neurosci. Lett. 372, 146-150 (2004). (Pubitemid 39505246)
23. Weise, J. et al. Deletion of cellular prion protein results in reduced Akt activation, enhanced postischemic caspase 3 activation, and exacerbation of ischemic brain injury. Stroke 37, 1296-1300 (2006). (Pubitemid 43731879)
24. Hoshino, S. et al. Prions prevent brain damage after experimental brain injury: a preliminary report. Acta Neurochir. Suppl. 86, 297-299 (2003).
25. Schmitt-Ulms, G. et al. Binding of neural cell adhesion molecules (N-CAMs) to the cellular prion protein. J. Mol. Biol. 314, 1209-1225 (2001). (Pubitemid 34073082)
26. Spielhaupter, C. & Schatzl, H. M. PrPC directly interacts with proteins involved in signaling pathways. J. Biol. Chem. 276, 44604-44612 (2001).
27. Kurschner, C. & Morgan, J. I. Analysis of interaction sites in homo- and heteromeric complexes containing Bcl 2 family members and the cellular prion protein. Brain Res. Mol. Brain Res. 37, 249-258 (1996).
28. Chiarini, L. B. et al. Cellular prion protein transduces neuroprotective signals. EMBO J. 21, 3317-3326 (2002). (Pubitemid 34760564)
29. Chen, S., Mange, A., Dong, L., Lehmann, S. & Schachner, M. Prion protein as trans interacting partner for neurons is involved in neurite outgrowth and neuronal survival. Mol. Cell. Neurosci. 22, 227-233 (2003). (Pubitemid 36379186)
30. Lopes, M. H. et al. Interaction of cellular prion and stress-inducible protein 1 promotes neuritogenesis and neuroprotection by distinct signaling pathways. J. Neurosci. 25, 11330-11339 (2005). (Pubitemid 43083707)
31. Vassallo, N. et al. Activation of phosphatidylinositol 3 kinase by cellular prion protein and its role in cell survival. Biochem Biophys. Res. Commun. 332, 75-82 (2005). (Pubitemid 40719459)
32. Skovronsky, D. M., Lee, V. M. & Trojanowski, J. Q. Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications. Annu. Rev. Pathol. 1, 151-170 (2006).
33. Parkin, E. T. et al. Cellular prion protein regulates β-secretase cleavage of the Alzheimer's amyloid precursor protein. Proc. Natl Acad. Sci. USA 104, 11062-11067 (2007). (Pubitemid 47175226)
34. Cisse, M. & Mucke, L. Alzheimer's disease: a prion protein connection. Nature 457, 1090-1091 (2009).
35. Kellett, K. A. & Hooper, N. M. Prion protein and Alzheimer disease. Prion 3, 190-194 (2009).
36. Wang, V., Chuang, T. C., Soong, B. W., Shan, D. E. & Kao, M. C. Octarepeat changes of prion protein in Parkinson's disease. Parkinsonism Relat. Disord. 15, 53-58 (2009).
37. Heppner, F. L. et al. Transepithelial prion transport by M cells. Nat. Med. 7, 976-977 (2001).
38. Aguzzi, A. & Sigurdson, C. J. Antiprion immunotherapy: to suppress or to stimulate? Nat. Rev. Immunol. 4, 725-736 (2004). (Pubitemid 39223078)
39. Daude, N. Prion diseases and the spleen. Viral Immunol. 17, 334-349 (2004). (Pubitemid 39244756)
40. Kimberlin, R. H. & Walker, C. A. The role of the spleen in the neuroinvasion of scrapie in mice. Virus Res. 12, 201-211 (1989).
41. Montrasio, F. et al. Impaired prion replication in spleens of mice lacking functional follicular dendritic cells. Science 288, 1257-1259 (2000). (Pubitemid 30367206)
42. Klein, M. A. et al. A crucial role for B cells in neuroinvasive scrapie. Nature 390, 687-690 (1997). (Pubitemid 28016356)
43. Klein, M. A. et al. PrP expression in B lymphocytes is not required for prion neuroinvasion. Nat. Med. 4, 1429-1433 (1998). (Pubitemid 28553468)
44. Mabbott, N. A. et al. Tumor necrosis factor alpha-deficient, but not interleukin 6 deficient, mice resist peripheral infection with scrapie. J. Virol. 74, 3338-3344 (2000). (Pubitemid 30143759)
45. Aguzzi, A. et al. Immune system and peripheral nerves in propagation of prions to CNS. Br. Med. Bull. 66, 141-159 (2003).
46. Nicotera, P. A route for prion neuroinvasion. Neuron 31, 345-348 (2001). (Pubitemid 32778554)
47. Glatzel, M., Heppner, F. L., Albers, K. M. & Aguzzi, A. Sympathetic innervation of lymphoreticular organs is rate limiting for prion neuroinvasion. Neuron 31, 25-34 (2001). (Pubitemid 32757086)
48. Prinz, M. et al. Positioning of follicular dendritic cells within the spleen controls prion neuroinvasion. Nature 425, 957-962 (2003). (Pubitemid 37376926)
49. Aguzzi, A. & Zhu, C. Five questions on prion diseases. PLoS Pathog. 8, e1002651 (2012).
50. Vella, L. J., Sharples, R. A., Nisbet, R. M., Cappai, R. & Hill, A. F. The role of exosomes in the processing of proteins associated with neurodegenerative diseases. Eur. Biophys. J. 37, 323-332 (2008).
51. Vella, L. J. & Hill, A. F. Generation of cell lines propagating infectious prions and the isolation and characterization of cell-derived exosomes. Methods Mol. Biol. 459, 69-82 (2008).
52. Leblanc, P. et al. Retrovirus infection strongly enhances scrapie infectivity release in cell culture. EMBO J. 25, 2674-2685 (2006). (Pubitemid 43980376)
53. Alais, S. et al. Mouse neuroblastoma cells release prion infectivity associated with exosomal vesicles. Biol. Cell 100, 603-615 (2008).
54. Schenk, D. et al. Immunization with amyloid-β attenuates Alzheimer disease like pathology in the PDAPP mouse. Nature 400, 173-177 (1999). (Pubitemid 29327547)
55. Morgan, D. et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408, 982-985 (2000). (Pubitemid 32101645)
56. Bard, F. et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6, 916-919 (2000). (Pubitemid 30644751)
57. Porter, D. D., Porter, H. G. & Cox, N. A. Failure to demonstrate a humoral immune response to scrapie infection in mice. J. Immunol. 111, 1407-1410 (1973).
58. Kasper, K. C., Stites, D. P., Bowman, K. A., Panitch, H. & Prusiner, S. B. Immunological studies of scrapie infection. J. Neuroimmunol. 3, 187-201 (1982). (Pubitemid 13169833)
59. Aucouturier, P. & Carnaud, C. The immune system and prion diseases: a relationship of complicity and blindness. J. Leukoc. Biol. 72, 1075-1083 (2002).
60. Spinner, D. S. et al. CpG oligodeoxynucleotide-enhanced humoral immune response and production of antibodies to prion protein PrPSc in mice immunized with 139A scrapie-associated fibrils. J. Leukoc. Biol. 81, 1374-1385 (2007). (Pubitemid 46827960)
61. Polymenidou, M. et al. Humoral immune response to native eukaryotic prion protein correlates with anti-prion protection. Proc. Natl Acad. Sci. USA 101 (Suppl. 2), 14670-14676 (2004). (Pubitemid 39346741)
62. Krasemann, S., Groschup, M. H., Harmeyer, S., Hunsmann, G. & Bodemer, W. Generation of monoclonal antibodies against human prion proteins in PrP0/0 mice. Mol. Med. 2, 725-734 (1996).
63. Demart, S. et al. New insight into abnormal prion protein using monoclonal antibodies. Biochem. Biophys. Res. Commun. 265, 652-657 (1999).
64. Bainbridge, J. & Walker, B. Cell mediated immune responses against human prion protein. Clin. Exp. Immunol. 133, 310-317 (2003). (Pubitemid 37046954)
65. Gregoire, S. et al. Identification of two immunogenic domains of the prion protein- PrP -which activate class II restricted T cells and elicit antibody responses against the native molecule. J. Leukoc. Biol. 76, 125-134 (2004). (Pubitemid 38857179)
66. Kim, C. L. et al. Antigenic characterization of an abnormal isoform of prion protein using a new diverse panel of monoclonal antibodies. Virology 320, 40-51 (2004).
67. Khalili-Shirazi, A. et al. Protein conformation significantly influences immune responses to prion protein. J. Immunol. 174, 3256-3263 (2005). (Pubitemid 40354028)
68. Nakamura, N. et al. Generation of antibodies against prion protein by scrapie-infected cell immunization of PrP0/0 mice. Hybrid Hybridomics 22, 263-266 (2003). (Pubitemid 37102755)
69. Trevitt, C. R. & Collinge, J. A systematic review of prion therapeutics in experimental models. Brain 129, 2241-2265 (2006). (Pubitemid 44522112)
70. Muller-Schiffmann, A. & Korth, C. Vaccine approaches to prevent and treat prion infection: progress and challenges. BioDrugs 22, 45-52 (2008). (Pubitemid 351158534)
71. Arbel, M., Lavie, V. & Solomon, B. Generation of antibodies against prion protein in wild-type mice via helix 1 peptide immunization. J. Neuroimmunol. 144, 38-45 (2003). (Pubitemid 37329927)
72. Bainbridge, J., Jones, N. & Walker, B. Multiple antigenic peptides facilitate generation of anti-prion antibodies. Clin. Exp. Immunol. 137, 298-304 (2004). (Pubitemid 39013075)
73. Souan, L. et al. Modulation of proteinase K resistant prion protein by prion peptide immunization. Eur. J. Immunol. 31, 2338-2346 (2001). (Pubitemid 32785352)
74. Schwarz, A. et al. Immunisation with a synthetic prion protein-derived peptide prolongs survival times of mice orally exposed to the scrapie agent. Neurosci. Lett. 350, 187-189 (2003). (Pubitemid 37205197)
75. Bachy, V. et al. Mouse vaccination with dendritic cells loaded with prion protein peptides overcomes tolerance and delays scrapie. J. Gen. Virol. 91, 809-820 (2010).
76. Koller, M. F., Grau, T. & Christen, P. Induction of antibodies against murine full-length prion protein in wild-type mice. J. Neuroimmunol. 132, 113-116 (2002). (Pubitemid 35333332)
77. Sigurdsson, E. M. et al. Immunization delays the onset of prion disease in mice. Am. J. Pathol. 161, 13-17 (2002). (Pubitemid 34760765)
78. Ishibashi, D. et al. Immunization with recombinant bovine but not mouse prion protein delays the onset of disease in mice inoculated with a mouse-adapted prion. Vaccine 25, 985-992 (2007). (Pubitemid 44937461)
79. Tayebi, M., Collinge, J. & Hawke, S. Unswitched immunoglobulin M response prolongs mouse survival in prion disease. J. Gen. Virol. 90, 777-782 (2009).
80. Ishibashi, D. et al. Antigenic mimicry-mediated anti-prion effects induced by bacterial enzyme succinylarginine dihydrolase in mice. Vaccine 29, 9321-9328 (2011).
81. Rosset, M. B. et al. Dendritic cell mediated immunization with xenogenic PrP and adenoviral vectors breaks tolerance and prolongs mice survival against experimental scrapie. PLoS ONE 4, e4917 (2009).
82. Bade, S., Baier, M., Boetel, T. & Frey, A. Intranasal immunization of Balb/c mice against prion protein attenuates orally acquired transmissible spongiform encephalopathy. Vaccine 24, 1242-1253 (2006). (Pubitemid 43222031)
83. Goni, F. et al. High titers of mucosal and systemic anti-PrP antibodies abrogate oral prion infection in mucosal-vaccinated mice. Neuroscience 153, 679-686 (2008).
84. Bayer, A. J. et al. Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD. Neurology 64, 94-101 (2005). (Pubitemid 40082943)
85. Schenk, D. Amyloid-β immunotherapy for Alzheimer's disease: the end of the beginning. Nat. Rev. Neurosci. 3, 824-828 (2002). (Pubitemid 135706694)
86. Solforosi, L. et al. Cross-linking cellular prion protein triggers neuronal apoptosis in vivo. Science 303, 1514-1516 (2004). (Pubitemid 38314420)
87. Klohn, P. C. et al. PrP antibodies do not trigger mouse hippocampal neuron apoptosis. Science 335, 52 (2012).
88. Heppner, F. L. et al. Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science 294, 178-182 (2001). (Pubitemid 32952973)
89. Sigurdsson, E. M. et al. Anti-prion antibodies for prophylaxis following prion exposure in mice. Neurosci. Lett. 336, 185-187 (2003). (Pubitemid 36044608)
90. White, A. R. et al. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 422, 80-83 (2003). (Pubitemid 36323299)
91. Sadowski, M. J. et al. Anti-PrP Mab 6D11 suppresses PrPSc replication in prion infected myeloid precursor line FDC P1/22L and in the lymphoreticular system in vivo. Neurobiol. Dis. 34, 267-278 (2009).
92. Zuber, C. et al. Anti-LRP/LR antibody W3 hampers peripheral PrPSc propagation in scrapie infected mice. Prion 1, 207-212 (2007).
93. Gauczynski, S. et al. The 37-kDa/67-kDa laminin receptor acts as a receptor for infectious prions and is inhibited by polysulfated glycanes. J. Infect. Dis. 194, 702-709 (2006). (Pubitemid 44297858)
94. Gauczynski, S. et al. The 37-kDa/67-kDa laminin receptor acts as the cell-surface receptor for the cellular prion protein. EMBO J. 20, 5863-5875 (2001). (Pubitemid 33049262)
95. Leucht, C. et al. The 37 kDa/67 kDa laminin receptor is required for PrPSc propagation in scrapie-infected neuronal cells. EMBO Rep. 4, 290-295 (2003). (Pubitemid 36511726)
96. Zuber, C. et al. Single chain Fv antibodies directed against the 37 kDa/67 kDa laminin receptor as therapeutic tools in prion diseases. Mol. Immunol. 45, 144-151 (2008). (Pubitemid 47336972)
97. Wei, X. et al. Human anti-prion antibodies block prion peptide fibril formation and neurotoxicity. J. Biol. Chem. 287, 12858-12866 (2012).
98. Kellner, A. et al. Autoantibodies against β-amyloid are common in Alzheimer's disease and control plaque burden. Ann. Neurol. 65, 24-31 (2009).
99. Dodel, R. C. et al. Intravenous immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 75, 1472-1474 (2004). (Pubitemid 39279821)
100. Relkin, N. R. et al. 18-month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol. Aging 30, 1728-1736 (2009).
101. Dorban, G., Defaweux, V., Heinen, E. & Antoine, N. Spreading of prions from the immune to the peripheral nervous system: a potential implication of dendritic cells. Histochem. Cell Biol. 133, 493-504 (2010).
102. Du, Y. et al. Human anti β amyloid antibodies block β-amyloid fibril formation and prevent β amyloid induced neurotoxicity. Brain 126, 1935-1939 (2003). (Pubitemid 37059433)
103. Dodel, R. et al. Naturally occurring autoantibodies against β-amyloid: investigating their role in transgenic animal and in vitro models of Alzheimer's disease. J. Neurosci. 31, 5847-5854 (2011).